Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy

NCT03402841 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03402841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03402841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
January 30, 2018
Completion date
March 10, 2022
Enrollment
279 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

non-germline brca mutated ovarian cancer